Talaris Therapeutics Past Earnings Performance
Past criteria checks 0/6
Talaris Therapeutics's earnings have been declining at an average annual rate of -40.8%, while the Biotechs industry saw earnings growing at 17.4% annually.
Key information
-40.8%
Earnings growth rate
24.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -50.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?
May 24
Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?
Feb 14We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
Oct 21Talaris drops 24% after patient death in late-stage trial for lead asset
Oct 20Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
Aug 29Talaris Therapeutics GAAP EPS of -$0.44
Aug 15We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
Jul 06Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial
Jun 30Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans
Mar 23Talaris Therapeutics EPS beats by $0.49
Jun 14Revenue & Expenses Breakdown
How Talaris Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -75 | 22 | 47 |
| 31 Mar 23 | 0 | -78 | 21 | 56 |
| 31 Dec 22 | 0 | -74 | 19 | 57 |
| 30 Sep 22 | 0 | -70 | 18 | 53 |
| 30 Jun 22 | 0 | -64 | 17 | 47 |
| 31 Mar 22 | 0 | -57 | 15 | 42 |
| 31 Dec 21 | 0 | -48 | 13 | 34 |
| 30 Sep 21 | 0 | -40 | 12 | 28 |
| 30 Jun 21 | 0 | -34 | 10 | 23 |
| 31 Mar 21 | 0 | -27 | 9 | 18 |
| 31 Dec 20 | 0 | -23 | 7 | 15 |
Quality Earnings: TALS is currently unprofitable.
Growing Profit Margin: TALS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TALS is unprofitable, and losses have increased over the past 5 years at a rate of 40.8% per year.
Accelerating Growth: Unable to compare TALS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TALS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: TALS has a negative Return on Equity (-50.38%), as it is currently unprofitable.